论文部分内容阅读
目的观察替米沙坦与二甲双胍联合治疗对高血压合并非酒精性脂肪性肝病(NAFLD)患者血压和糖脂代谢的影响。方法高血压合并NAFLD患者60例根据治疗方案分为对照组和观察组,对照组单用替米沙坦治疗,观察组给予替米沙坦和二甲双胍联合治疗,观察时间6月。观察两组治疗前后血压、腰臀比、体质量指数(BMI)、总胆固醇、三酰甘油、低密度脂蛋白胆固醇(LDL-C)、稳态模型胰岛素抵抗指数(HOMA-IR)、胰岛素分泌指数(HOMAβ)和胰岛素敏感指数(ISI)等指标变化。结果治疗前两组患者的基线资料、血压、血脂和糖代谢指标差异无统计学意义(P>0.05)。治疗6月后,与治疗前比较,两组患者血压、血脂和糖代谢指标得到改善(均P<0.05);与对照组比较,观察组患者的血压、血脂和糖代谢指标改善更明显(均P<0.05)。结论替米沙坦与二甲双胍联合治疗能够改善高血压合并NAFLD患者的血压和糖脂代谢。
Objective To observe the effect of combination therapy of telmisartan and metformin on blood pressure and glucose and lipid metabolism in patients with hypertension complicated with non-alcoholic fatty liver disease (NAFLD). Methods Sixty patients with hypertension and NAFLD were divided into control group and observation group according to the treatment regimen. The control group was treated with telmisartan alone. The observation group was treated with telmisartan and metformin. The observation time was 6 months. Blood pressure, WHR, BMI, TG, LDL-C, HOMA-IR, Index (HOMAβ) and insulin sensitivity index (ISI) and other indicators of change. Results There was no significant difference in baseline data, blood pressure, blood lipid and glucose metabolism between the two groups before treatment (P> 0.05). After 6 months of treatment, the indexes of blood pressure, blood lipid and glucose metabolism were improved in both groups (all P <0.05) compared with that before treatment. Compared with the control group, the indexes of blood pressure, blood lipid and glucose metabolism in the observation group improved more obviously P <0.05). Conclusion The combination therapy of telmisartan and metformin can improve blood pressure and glucose and lipid metabolism in hypertensive patients with NAFLD.